Mevalonate (lithium salt) (Synonyms: Mevalonic Acid, MVA, Pentanoic Acid) |
Catalog No.GC52250
One-Click Copy Product Info
|
Mevalonate (lithium salt) is a metabolic precursor of the mevalonate pathway.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2618458-93-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Mevalonate (lithium salt) is a metabolic precursor of the mevalonate pathway[1]. As a substrate supplement for this pathway, Mevalonate (lithium salt) is mainly utilized to investigate its key role in cell growth, proliferation, cholesterol synthesis, and protein prenylation[2]. Mevalonate (lithium salt) is commonly used in research on cardiovascular diseases, neurological disorders, metabolic diseases, and cancer[3][4].
In vitro, treatment of FRTL-5 thyroid epithelial cells with Mevalonate (lithium salt) (700µM; 2h) completely reversed mevinolin-induced cytoskeletal disruption, restored polygonal morphology, reorganized actin stress fibers and cortical actin networks, and re-established microtubule architecture[5]. Mevalonate (lithium salt) (5-20mM; 8-72h) dose-dependently inhibited acid sphingomyelinase activity, increased cellular cholesterol levels, elevated sphingomyelin and phosphatidylcholine content, and suppressed proliferation in HepG2 and Caco-2 cells[6].
In vivo, Mevalonate (lithium salt) (100mg/kg/day; i.p.; 14 days) enhanced anti-PD-L1 antibody efficacy, upregulated tumor PD-L1 expression, increased CD8+ and CD3+ T cell infiltration, and elevated IFN-γ, IL-2, and TNF-α secretion in CT26 colon cancer-bearing BALB/c mice[7].
References:
[1] Dellas N, Thomas ST, Manning G, Noel JP. Discovery of a metabolic alternative to the classical mevalonate pathway. Elife. 2013;2:e00672.
[2] Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-430.
[3] Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9-10):575-584.
[4] Juarez D, Fruman DA. Targeting the Mevalonate Pathway in Cancer. Trends Cancer. 2021;7(6):525-540.
[5] Bifulco M, Laezza C, Aloj SM, Garbi C. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol. 1993;155(2):340-348.
[6] Chen Y, Xu SC, Duan RD. Mevalonate inhibits acid sphingomyelinase activity, increases sphingomyelin levels and inhibits cell proliferation of HepG2 and Caco-2 cells. Lipids Health Dis. 2015;14:130.
[7] Zhang W, Pan X, Xu Y, et al. Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA. Acta Pharm Sin B. 2023;13(6):2585-2600.
| Cell experiment [1]: | |
|
Cell lines |
HepG2 and Caco-2 cells |
|
Preparation Method |
HepG2 and Caco-2 cells were cultured in monolayer in RPMI-1640 medium and DMEM medium, respectively, containing 4.5μg/l glucose, 2mM glutamine, 10% heat inactivated FBS, 100IU/ml penicillin and 10μg/ml streptomycin. Mevalonate (lithium salt) was dissolved in the culture medium as a stock and added in the cell culture medium to final concentrations examined. In the control group, only the culture medium was added. After incubation, the cells were scraped, lysed and sonicated. After centrifugation at 10000g at 4°C for 10min, the activities of SMases in the homogenate were determined. For kinetic studies, one day after the subculture, the cells were treated with Mevalonate (lithium salt) (5-20mM) for 8, 24, 48 and 72h and the acid SMase activities were determined. The changes of the activity after mevalonate treatment were expressed as percentage of the values before Mevalonate (lithium salt) treatment (0 time value). The cell proliferation was assay by MTT Cell Proliferation Assay kit. |
|
Reaction Conditions |
5-20mM; 8-72h |
|
Applications |
Mevalonate (lithium salt) dose-dependently inhibited acid sphingomyelinase activity and suppressed proliferation in HepG2 and Caco-2 cells. |
| Animal experiment [2]: | |
|
Animal models |
BALB/c male mice |
|
Preparation Method |
CT26 tumors were constructed subcutaneously injecting CT26 cells (5×105 per mouse in a 100mL medium) into 6-week-old BALB/c male mice. Tumor volumes were measured every day. Mice were pooled and randomly divided into four groups with comparable average tumor size. Mice were grouped into control (PBS), Mevalonate (lithium salt), anti-mouse PD-L1 and Mevalonate (lithium salt) plus anti-mouse PD-L1 treatment. PBS or Mevalonate (lithium salt) were treated daily by intraperitoneal injection (100mg/kg), and antimouse PD-L1 treatment was given twice a week by intravenous injection (5mg/kg). Mice were euthanized 14 days after drug treatment or if the tumor volume exceeded 2000mm3 . Mouse tumors tissues were collected for western blot analysis and ELISA assay of tumor cytokines. |
|
Dosage form |
100mg/kg/day; i.p.; 14 days |
|
Applications |
Mevalonate (lithium salt) enhanced anti-PD-L1 antibody efficacy, upregulated tumor PD-L1 expression, and elevated IFN-γ, IL-2, and TNF-α secretion in CT26 colon cancer-bearing BALB/c mice. |
|
References: |
|
| Cas No. | 2618458-93-6 | SDF | |
| Synonyms | Mevalonic Acid, MVA, Pentanoic Acid | ||
| Canonical SMILES | O=C(CC(O)(CCO)C)O.[Li] | ||
| Formula | C6H11LiO4 | M.Wt | 154.09 |
| Solubility | H2O : 100 mg/mL (648.97 mM; Need ultrasonic); DMSO : 50 mg/mL (324.49 mM; Need ultrasonic) | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.4897 mL | 32.4486 mL | 64.8971 mL |
| 5 mM | 1.2979 mL | 6.4897 mL | 12.9794 mL |
| 10 mM | 649 μL | 3.2449 mL | 6.4897 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)